Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mixing particles from various HCV genotypes increases the HBV-HCV vaccine ability to elicit broadly cross-neutralizing antibodies.

Liver international : official journal of the International Association for the Study of the Liver - 1 Aug 2020

Beaumont Elodie, Joël Clément Benoit, Guérin Vanessa, Chopin Lucie, Roch Emmanuelle, Gomez-Escobar Elsa, Roingeard Philippe

Abstract excerpt

The development of a safe, effective and affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. Hepatitis B-C subviral envelope particles, which could be produced by industrial procedures adapted from those established for the hepatitis B virus vaccine, appear promising for use for this purpose. The prototype HBV-HCV bivalent vaccine-bearing genotype 1a HCV envelopes can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Broadly Neutralizing Antibodies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B virus

Share to Hepatitis C

Share to Hepatitis C Antibodies

Share to Viral Envelope Proteins

Share to Viral Hepatitis Vaccines

Source

Identifiers

PMID: 32458507
DOI: 10.1111/liv.14541

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mixing particles from various HCV genotypes increases the HBV-HCV vaccine ability to elicit broadly cross-neutralizing antibodies.PMID 32458507Read ↗

Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine.Semantic proximity Read ↗

Development of Virus-Like Particles (VLPs) for Hepatitis C Virus genotype 4: a novel approach for vaccine development in Egypt.Semantic proximity Read ↗

From Structural Studies to HCV Vaccine Design.Semantic proximity Read ↗

A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in HumansSemantic proximity Read ↗

Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice.Semantic proximity Read ↗

Hepatitis C virus E1 protein-specific linear B-cell epitopes, pan-genotype reactivity, and functional relevance.Semantic proximity Read ↗

Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus.Semantic proximity Read ↗

Adenoviruses vectored hepatitis C virus vaccine cocktails induce broadly specific immune responses against multi-genotypic HCV in mice.Semantic proximity Read ↗

Hepatitis C cross-genotype immunity and implications for vaccine development.Semantic proximity Read ↗

Prospects for prophylactic and therapeutic vaccines against hepatitis C virus.Semantic proximity Read ↗

Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy.Semantic proximity Read ↗

Recombinant Flag-tagged E1E2 glycoproteins from three hepatitis C virus genotypes are biologically functional and elicit cross-reactive neutralizing antibodies in mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.